Biosimilars

Biosimilars

The NHS LPP MOPP workstream continue to track the prescribing uptake of biosimilar Adalimumab, Etanercept, Infliximab, Rituximab, Teriparatide and Trastuzumab. This is shared with stakeholders on a monthly basis including lost opportunity information. The savings on biosimilar uptake is reported quarterly as a part of the overall NHS LPP MOPP savings report.

 

More information
March 2018 - Report on uptake of Biosimilars in London (updated with December 2017 data)
This content is only available for NHS LPP members